Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

New capital secures future as key catalysts approach

Imricor Medical Systems
3:27pm
April 4, 2025
IMR is now well funded following a successful A$70m capital raising and is set to achieve a number of value adding catalysts. We are focused on the first ventricular tachycardia procedure, additional sales in Europe (and Middle East) and FDA approval for atrial flutter later in the year. Each catalyst has the potential to re-rate the share price. After adjusting our model for the capital raising and increasing the number of procedures per site from FY27 our DCF valuation has increased to A$2.28 (was $2.18). IMR is a key pick and we maintain our speculative buy recommendation.

Another horse in the race

Tasmea
3:27pm
April 3, 2025
TEA is acquiring Kalgoorlie based Flanco Group for $27m upfront consideration (2.6x EBIT based on expected maintainable EBIT of $10.2m). There are also additional annual earn-out payments up to $27m and uncapped overperformance payments. Using the base case of $10.2m EBIT in the first year and +15% growth per annum thereafter (in line with other TEA subsidiary targets), we assume the total consideration is $43m or 4.2x EBIT. This is consistent with recent acquisitions. Adjusting our forecasts to include Flanco, FY25 (2 months) EBIT and EPS each increase by +2%. In FY26, the first full year of ownership, EBIT increases by +11% and EPS by +8%. Based on continued earnings growth, supported by a conservative balance sheet and constructive industry tailwinds, we retain our ADD rating, increasing our 12-month target price to $3.80 (previously $3.65).

Another couple of positives

Findi
3:27pm
April 2, 2025
FND has updated the market on: 1) the impact of a change in the Indian interchange fee level; 2) the redeeming of its Compulsory Convertible Debentures (CCDs); and 3) a capital raising (A$40m institutional placement and A$5m SPP). The interchange fee changes and redemption of the CCDs are earnings positive, adding ~+A$14m to NPAT from FY27. We lift our FND FY26F/FY27F NPAT forecasts by +A$2m/+A$10m. Some of the upgrades for the interchange fee change and CCD restructure are offset by higher normal interest expense, tied to Brown Label ATM capex spend. Our target price rises to A$8.35 (from A$7.95). FND management are executing well on the company’s overall build out and with significant upside potential existing to our price target, we maintain our ADD call.

CTI and ROTE targets, UNITE update

Westpac Banking Corp
3:27pm
April 1, 2025
WBC’s new CEO hosted a market update which, amongst other things, provided FY29 CTI and ROTE targets, discussed the UNITE technology simplification program, and gave business unit updates. We’ve made forecast upgrades and lifted our 12 month target price to $29.02. WBC remains our preferred major bank, albeit potential TSR at current prices is -3%. Next key event is the 1H25 result due 5 May.

The Pursuit of Ravensthorpe

Medallion Metals
3:27pm
March 31, 2025
MM8 continues to progress the Ravensthorpe Gold Project (RGP) from concept to reality. The company has received multiple funding and offtake proposals from various counterparties, including project financing offers of up to A$50m, permitting efforts remain underway. Exclusive negotiations with ASX-listed IGO Ltd for the acquisition of the Forrestania processing infrastructure are advancing, with binding documentation well progressed. MM8 anticipates completion of negotiations within the 12-month exclusivity period. We reiterate our SPECULATIVE BUY rating, increasing our target price to A$0.41ps (from A$0.32ps).

Right Time, Right Place, Right Commodity

Meeka Metals
3:27pm
March 31, 2025
Development of the Murchison Gold Project (MGP) is tracking well to schedule with first gold due mid-2025. Expansions work on the process plant are progressing to schedule. Key infrastructure of the larger 750kW ball mill, cyclone cluster and structures have been installed. Open pit mining has commenced ahead of schedule with mining rates ramping up well, achieving ~20kBCM (Bank Cubic Meter) per pay, first ore is expected in April. We reiterate our SPECULATIVE BUY rating, increasing our target price to A$0.25ps (previously A$0.23ps) a function of increased spot gold prices.

Remaining hope fades as second Phase 3 fails

Opthea
3:27pm
March 31, 2025
After disappointing results in the Phase 3 COAST trial, showing lead drug candidate sozinibercept combined with standard of care (SOC) Eylea failed to show an improvement in mean change in best correct visual acuity (BCVA) at 52 weeks, the primary endpoint, the company opted to accelerate the readout of its other Phase 3 trial (ShORe), comparing sozinibercept with SOC Lucentis over the same timeframe and with the same primary endpoint. Like COAST, the ShORe trial failed to demonstrate any statistical difference in BCVA when comparing sozinibercept combination therapy with SOC. Management continues to access its obligations under a 2002 inked development funding agreement (DFA), where the company may be required to pay amounts that could material impact its solvency.

27 months to get back on track…a challenging goal

Healius
3:27pm
March 31, 2025
The investor day provided an update on the Lumus sale (closes 1 May-25; cA$300m special dividend (41.3c/sh fully franked)), a brief trading update (volumes +4%, revenue +6.2%), and importantly, the go forward strategy, which aims for operating leverage in the high single digit range by the end of FY27. Management’s ‘T27 plan’ aspires to grow revenue and lower the cost base via improved workforce planning and digital enablement across customer service, lab modernisation and emerging diagnostics. While management is confident the right ingredients are in place to succeed, with only 30% of flagged milestones completed to date, and an estimated A$110m+ in cost savings/efficiencies (>10% of the cost base) required to deliver on the goal, we view it as challenging. We adjust FY25-27 estimates with our target price falling to $1.32 from $1.35. Hold.

A great buy

The Reject Shop
3:27pm
March 27, 2025
TRS has entered into a scheme implementation agreement with Dollarama (DOL-TSX) to acquire all shares for $6.68 per share, which is a 112% premium to the previous closing price. This values TRS equity at A$259m. We think this is a strong offer which represents 95% upside to our previously published target price of $3.50. We move our price target to align with the TRS scheme offer price of $6.68 per share. Given the share price is now trading in line with the offer price, we retain a HOLD recommendation.

Strong heartbeat

EBR Systems
3:27pm
March 27, 2025
CY25 results were in line with expectations, with adequate funding for more than six quarters at the current burn. We see little risk to FDA approval for the company’s wireless cardiac pacing device (WiSE) on or before 13 Apr-25, with 2H25 launch. We view commercial and manufacturing readiness, along with a reimbursement path that is both streamlined and incentivised, as helping to smooth the transition from developmental stage into a commercially viable medical device business. We make nominal changes to CY25-26 forecasts, but raise our DCF-based valuation to A$2.86 (from A$1.76) on increased probability of FDA approval. Speculative Buy maintained.

News & Insights

Michael Knox, Chief Economist looks at what might have happened in January 2026 if the cuts in corporate tax rates in Trumps first term were not renewed and extended in the One Big Beautiful Bill

In recent weeks, a number of media commentators have criticized Donald Trump's " One big Beautiful Bill " on the basis of a statement by the Congressional Budget Office that under existing legislation the bill adds $US 3.4 trillion to the US Budget deficit. They tend not to mention that this is because the existing law assumes that all the tax cuts made in 2017 by the first Trump Administration expire at the end of this year.

Let’s us look at what might have happened in January 2026 if the cuts in US corporate tax rates in Trumps first term were not renewed and extended in the One Big Beautiful Bill.

Back in 2016 before the first Trump administration came to office in his first term, the US corporate tax rate was then 35%. In 2017 the Tax Cut and Jobs Act reduced the corporate tax rate to 21%. Because this bill was passed as a "Reconciliation Bill “, This meant it required only a simple majority of Senate votes to pass. This tax rate of 21% was due to expire in January 2026.

The One Big Beautiful Bill has made the expiring tax cuts permanent; this bill was signed into law on 4 July 2025. Now of course the same legislation also made a large number of individual tax cuts in the original 2017 bill permanent.

What would have happened if the bill had not passed. Let us construct what economists call a "Counterfactual"

Let’s just restrict ourselves to the case of what have happened in 2026 if the US corporate tax had risen to the prior rate of 35%.

This is an increase in the corporate tax rate of 14%. This increase would generate a sudden fall in US corporate after-tax earnings in January 2026 of 14%. What effect would that have on the level of the S&P 500?

The Price /Earnings Ratio of the S&P500 in July 2025 was 26.1.

Still the ten-year average Price/ Earnings Ratio for the S&P500 is only 18.99. Let’s say 19 times.

Should earnings per share have suddenly fallen by 14%, then the S&P 500 might have fallen by 14% multiplied by the short-term Price/ Earnings ratio.

This means a likely fall in the S&P500 of 37%.

As the market recovered to long term Price Earnings ratio of 19 this fall might then have ben be reduced to 27%.

Put simply, had the One Big, beautiful Bill not been passed, then in 2026 the US stock market might suddenly have fallen by 37% before then recovering to a fall of 27% .

The devastating effect on the US and indeed World economy might plausibly have caused a major recession.

On 9 June Kevin Hassert the Director of the National Economic Council said in a CBS interview with Margaret Brennan that if the bill did not pass US GDP would fall by 4% and 6-7 million Americans would lose their jobs.

The Passage of the One Big Beautiful Bill on 4 July thus avoided One Big Ugly Disaster.

Read more
On 7 July the AFR published a list of 37 Economists who had answered a poll on when the RBA would next cut rates. 32 of them thought that the RBA would cut on 8 July. Only 5 of them did not believe the RBA would cut, Michael Knox being one of them.

On 7 July the AFR published a list of 37 Economists who had answered a poll on when the RBA would next cut rates. 32 of them thought that the RBA would cut on 8 July. Only 5 of them did not believe the RBA would cut on 8 July. I was one of them. The RBA did not cut.

So today I will talk about how I came to that decision. First, lets look at our model of official interest rates. Back in January 2015 I went to a presentation in San Franciso by Stan Fishcer . Stan was a celebrated economist who at that time was Ben Bernanke's deputy at the Federal Reserve. Stan gave a talk about how the Fed thought about interest rates.

Stan presented a model of R*. This is the real short rate of the Fed Funds Rate at which monetary policy is at equilibrium. Unemployment was shown as a most important variable. So was inflationary expectations.

This then logically lead to a model where the nominal level of the Fed funds rate was driven by Inflation, Inflationary expectations and unemployment. Unemployment was important because of its effect on future inflation. The lower the level of unemployment the higher the level of future inflation and the higher the level of the Fed funds rate. I tried the model and it worked. It worked not just for the Fed funds rate. It also worked in Australia for Australian cash rate.

Recently though I have found that while the model has continued to work to work for the Fed funds rate It has been not quite as good in modelling that Australian Cash Rate. I found the answer to this in a model of Australian inflation published by the RBA. The model showed Australian Inflation was not just caused by low unemployment, It was also caused by high import price rises. Import price inflation was more important in Australia because imports were a higher level of Australian GDP than was the case in the US.

This was important in Australia than in the US because Australian import price inflation was close to zero for the 2 years up to the end of 2024. Import prices rose sharply in the first quarter of 2025. What would happen in the second quarter of 2025 and how would it effect inflation I could not tell. The only thing I could do is wait for the Q2 inflation numbers to come out for Australia.

I thought that for this reason and other reasons the RBA would also wait for the Q2 inflation numbers to come out. There were other reasons as well. The Quarterly CPI was a more reliable measure of the CPI and was a better measure of services inflation than the monthly CPI. The result was that RBA did not move and voiced a preference for quarterly measure of inflation over monthly version.

Lets look again at R* or the real level of the Cash rate for Australia .When we look at the average real Cash rate since January 2000 we find an average number of 0.85%. At an inflation target of 2.5 % this suggests this suggest an equilibrium Cash rate of 3.35%

Model of the Australian Cash Rate.
Model of the Australian Cash Rate


What will happen next? We think that the after the RBA meeting of 11 and 12 August the RBA will cut the Cash rate to 3.6%

We think that after the RBA meeting of 8 and 9 December the RBA will cut the Cash rate to 3.35%

Unless Quarterly inflation falls below 2.5% , the Cash rate will remain at 3.35% .

Read more
Investment Watch is a quarterly publication for insights in equity and economic strategy. Recent months have been marked by sharp swings in market sentiment, driven by shifting global trade dynamics, geopolitical tensions, and policy uncertainty.

Investment Watch is a quarterly publication produced by Morgans that delves into key insights for equity and economic strategy.

This publication covers

Economics - 'The challenge of Australian productivity' and 'Iran, from the Suez blockade to the 12 day war'
Asset Allocation
- 'Prioritise portfolio resilience amidst the prevailing uncertainty'
Equity Strategy
- 'Rethinking sector preferences and portfolio balance'
Fixed Interest
- 'Market volatility analysis: Low beta investment opportunities'
Banks
- 'Outperformance driving the broader market index'
Industrials
- 'New opportunities will arise'
Resources and Energy
- 'Getting paid to wait in the majors'
Technology
- 'Buy the dips'
Consumer discretionary
- 'Support remains in place'
Telco
- 'A cautious eye on competitive intensity'
Travel
- 'Demand trends still solid'
Property
- 'An improving Cycle'

Recent months have been marked by sharp swings in market sentiment, driven by shifting global trade dynamics, geopolitical tensions, and policy uncertainty. The rapid pace of US policy announcements, coupled with reversals, has made it difficult for investors to form strong convictions or accurately assess the impact on growth and earnings. While trade tariffs are still a concern, recent progress in US bilateral negotiations and signs of greater policy stability have reduced immediate headline risks.

We expect that more stable policies, potential tax cuts, and continued innovation - particularly in AI - will support a gradual pickup in investment activity. In this environment, we recommend prioritising portfolio resilience. This means maintaining diversification, focusing on quality, and being prepared to adjust exposures as new risks or opportunities emerge. This quarter, we update our outlook for interest rates and also explore the implications of the conflict in the Middle East on portfolios. As usual, we provide an outlook for the key sectors of the Australian market and where we see the best tactical opportunities.


Morgans clients receive exclusive insights such as access to our latest Investment Watch publication. Contact us today to begin your journey with Morgans.

      
Contact us
      
      
Find an adviser
      
Read more